Targeting angiogenesis in myocardial infarction: Novel therapeutics
J Li, Y Zhao, W Zhu - Experimental and therapeutic …, 2022 - spandidos-publications.com
Acute myocardial infarction (AMI) remains the main cause of mortality worldwide. Despite
surgery and medical treatment, the non‑regeneration of dead cardiomyocytes and the …
surgery and medical treatment, the non‑regeneration of dead cardiomyocytes and the …
[PDF][PDF] Terapia biológica no tratamento da psoríase moderada a grave: revisão sistemática Biological therapy in the treatment of moderate to severe psoriasis …
CF Jacquiminut, GM Azevedo… - Brazilian Journal of …, 2021 - scholar.archive.org
RESUMO INTRODUÇÃO: A Psoríase é uma doença inflamatória crônica que acomete
principalmente a pele e as articulações. Em pacientes com psoríase moderada ou grave …
principalmente a pele e as articulações. Em pacientes com psoríase moderada ou grave …
Evidence on the therapeutic role of thiolutin in imiquimod‐induced psoriasis‐like skin inflammation in mice
A Wang, X Ma, F Wei, Y Li, Q Liu… - Immunity, Inflammation …, 2023 - Wiley Online Library
Introduction A recent study confirmed that thiolutin (THL), as a potent inflammasome
inhibitor, plays a promising therapeutic role in multiple inflammatory disease models …
inhibitor, plays a promising therapeutic role in multiple inflammatory disease models …
[HTML][HTML] Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective …
IO Topal, S Baysak, İK Altunay, AK Polat… - Anais Brasileiros de …, 2022 - SciELO Brasil
Background: Clinical studies have demonstrated that IL-17A inhibition with secukinumab is
effective for clearing the skin of patients with psoriasis and has a favorable safety profile …
effective for clearing the skin of patients with psoriasis and has a favorable safety profile …
[HTML][HTML] Qingxiong Ointment and its Active Ingredient, Shikonin Treat Psoriasis through HIF-1 Signaling Pathway
B Zhang, G Yan, F Li, Y Tang, G Xu… - Current Pharmaceutical …, 2024 - freezetech.ru
Background: Psoriasis is a common chronic inflammatory skin disorder. Qingxiong ointment
(QX) is a natural medicinal combination frequently employed in clinical treatment of …
(QX) is a natural medicinal combination frequently employed in clinical treatment of …
[PDF][PDF] Anais Brasileiros de
E Kocatürk, EB Baskan, ÖS Küçük… - Anais Brasileiros …, 2022 - anaisdedermatologia.org.br
Fundamentos: A urticária crônica espontânea (UCE) é caracterizada por urticas e/ou
angioedema recorrentes por mais de seis semanas. As diretrizes recomendam …
angioedema recorrentes por mais de seis semanas. As diretrizes recomendam …
Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor-Secukinumab
A Milidrag, M Gutić, I Rodić, A Pjevač… - … and Applied Biomedical … - sciendo.com
Secukinumab is fully human monoclonal antibody, IgG-1κ, which selectively attaches to IL-
17A and inhibits its effects, which subsequently leads to a decrease of local inflammatory …
17A and inhibits its effects, which subsequently leads to a decrease of local inflammatory …
[PDF][PDF] Secukinumab in psoriasis: A single-center experience
Abstract Background and Design: Several randomized clinical trials demonstrated the safety
and efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; …
and efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; …
Secukinumab in psoriasis: A single-center experience/Psoriaziste sekukinumab: Tek merkez deneyimi.
Background and Design: Several randomized clinical trials demonstrated the safety and
efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; however …
efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; however …
[引用][C] Hur stor är risken för trombocytopeni vid behandling med IL-17-hämmare och TNF-alfa-hämmare?
O RELIS, R Midt-Norge, R Vest, R Nord-Norge…